64Cu-LNTH-1363S not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,”In the company’s words, NCT06298916 on ClinicalTrials.gov
- Tested for
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
- Main trialPhase 1/2
- “This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).”In the company’s words, NCT06298916 on ClinicalTrials.gov
Other drugs for Esophageal Cancer
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- DurvalumabAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Nov 2025 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026